Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Restrictive vs Liberal RBC Transfusion in Cirrhosis with Septic Shock
NCT03433508Withdrawn
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Dec 2018
- Primary completion
- Feb 2019
- Modality
- Recombinant Proteins and Enzymes, Cell Therapies
- Countries
- 1
01
Overview
Randomised, open-label trial of red blood cells in septic shock and Cirrhosis (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Mortality in both groups at 28 days. Planned start Dec 2018; status: withdrawn.
02
Drugs
red blood cells
03
Conditions
septic shockCirrhosis
Beyond the preview
Go deeper on NCT03433508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03433508.